Pila Pharma AB (FRA:5KC) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


FRA:5KC Pila Pharma AB FRA:5KC
49 GF Score
Price €0.10
GF Value €0.15
! 3 Warning Signs
View Full Analysis

What is Pila Pharma AB Research & Development?

Pila Pharma AB FRA:5KC -3.24% 49 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:5KC with a GF Score™ of 49/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pila Pharma AB's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Pila Pharma AB  (FRA:5KC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pila Pharma AB Research & Development Related Terms

Pila Pharma AB Research & Development Historical Data

* Premium members only.

The historical data trend for Pila Pharma AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pila Pharma AB Research & Development Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pila Pharma AB Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:5KC
49GF Score
Pila Pharma AB FRA:5KC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pila Pharma AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Pila Pharma AB (FRA:5KC) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Pila Pharma AB and its competitors.
Is Pila Pharma AB's Research & Development too high?
Pila Pharma AB's current Research & Development is €0.00 Mil. Overall, Pila Pharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's Research & Development compare to VRTX and REGN?
Pila Pharma AB's Research & Development of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pila Pharma AB and its competitors. Pila Pharma AB's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €0.15, compared to a current price of €0.10 — trading 30.3% below its estimated fair value. The current Research & Development is €0.00 Mil. Pila Pharma AB's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?

Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued. The current stock price of €0.10 is trading 30.3% below its estimated GF Value™ of €0.15.

Key valuation signals for FRA:5KC:

  • Research & Development: €0.00 Mil
  • GF Value™: €0.15 vs. price of €0.10 (30.3% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pila Pharma AB Business Description

Other Exchanges PILA:Sweden
Address Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
49GF Score

Get the complete analysis for FRA:5KC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.15
GF Value